The race for weight-loss drug dominance is about to get more interesting. U.S. regulators are reportedly mulling whether to dramatically speed up the review process for Eli Lilly and Co. (LLY)'s experimental oral obesity treatment, orforglipron, potentially shaving weeks off the approval timeline.

According to internal documents cited by Reuters, the FDA Commissioner's Office has been pushing staff to slash the standard 60-day filing check—basically the initial pass to confirm an application is complete—down to just one week for certain drugs under a new expedited pathway. The initiative falls under the National Priority Voucher program, which launched in June and is designed to fast-track products addressing urgent public health or national security concerns.

But not everyone at the agency was thrilled with the aggressive timeline. After internal resistance from staff, the Commissioner's Office softened its stance, suggesting filing reviews might instead be shortened to two or three weeks, depending on how complex the application turns out to be.

What This Means for Lilly's Timeline

Here's where it gets interesting for investors: if the FDA does implement a compressed review schedule, Eli Lilly (LLY)'s target approval date could shift to late March—significantly ahead of the current May 20 deadline set by reviewers, according to Reuters. That's not a done deal yet, and it's still unclear whether the agency will formally adopt these changes, but the pressure is mounting.

The timing matters because Novo Nordisk A/S (NVO) is expected to launch its own weight-loss pill sometime in December or January. Getting to market first, or at least not falling too far behind, could make a meaningful difference in capturing market share in what's shaping up to be one of the most lucrative pharmaceutical categories in years.

Under the voucher program rules, companies must submit manufacturing data and draft labeling 60 days before their final application. By law, the FDA then has two months to complete the final review, creating a total expected review timeline of roughly six months.

Novo Nordisk Makes Its Move in India

While the FDA deliberates, Novo Nordisk (NVO) isn't sitting idle. The company launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week as it moves to establish a foothold in one of the world's largest diabetes and obesity markets.

Reuters reported that the drug will be available in pen formats across three strengths: 0.25 mg, 0.5 mg, and 1 mg, priced at 8,800 rupees, 10,170 rupees, and 11,175 rupees per month, respectively. Each pen contains four weekly doses.

The pricing is significant because analysts expect these figures to set the benchmark for semaglutide generics scheduled to arrive next quarter. India represents the second-largest market for type 2 diabetes after China, making it a critical growth opportunity that Novo can't afford to fumble.

Meanwhile, major Indian pharmaceutical companies including Sun Pharma, Cipla, Dr. Reddy's Laboratories Ltd. (RDY), and Lupin are all working to bring their own semaglutide generics to market, which should make pricing dynamics particularly interesting to watch.

Eli Lilly (LLY) shares were up 0.87% at $1,018.14 during premarket trading on Friday, according to market data.